Novel streptogramin antibiotics

Expert Opinion on Investigational Drugs

Volumn 10, Issue 2, 2001, Pages 185-198

  Bonfiglio, G ^a   Furneri, P M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antibiotics; Enterococcus faecium; Gram positive bacteria; Quinupristin dalfopristin; Streptogramin; Vancomycin resistant enterococci

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL PROTEIN; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; DOXYCYCLINE; DRUG METABOLITE; ERYTHROMYCIN; IMIPENEM; MACROLIDE; METICILLIN; MIKAMYCIN B; NOVOBIOCIN; OXACILLIN; PENICILLIN G; PRISTINAMYCIN; QUINUPRISTIN; RIFAMPICIN; RPR 106972; SPARFLOXACIN; STREPTOGRAMIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRGINIAMYCIN S; WATER;

ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VIVO STUDY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PNEUMONIA; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RIBOSOME; SKIN INFECTION; STREPTOMYCES;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; HUMANS; VIRGINIAMYCIN;

EID: 0035150582     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.2.185     Document Type: Review

References (96)

1. Antibiotics of the virginiamycin family, inhibitions which contain synergistic component
2. The chemistry of pristinamycin
3. RP-59000: A proposed mechanism for its bactericidal activity
4. Recent developments in streptogramin research
5. Mechanisms of action of the macrolide and streptogramin antibiotics
6. The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes
7. Inhibition of protein synthesis by streptogramins and related antibiotics
8. Antagonistic interactions of macrolide and synergymycins on bacterial ribosomes
9. Molecular mechanism of virginiamycin-like antibiotics on bacterial cell free systems for protein synthesis
10. Interference of virginiamycin M with the initiation and the elongation of peptide chains in cell-free systems
11. Virginiamycin M - A specific inhibitor of the acceptor site of ribosomes
12. The action of virginiamycin M on the acceptor, donor and catalytic sites of peptidyltransferase
13. Vernamycin A inhibits the non enzymatic binding of fMet-tRna to ribosomes
14. Analysis of the reversible binding of virginiamycin M to ribosome and particle functions after removal of the antibiotic
15. Ribosome protection by tRNA derivatives against inactivation by virginiamycin M. Evidences for 2 types of interaction of tRNA with the donor site of the peptidyltransferase
16. Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides
17. Action of erythromycin and virginiamycin S on polypeptides synthesis in cell-free systems
18. Analysis of fluorescence quenching of ribosome-bound virginiamycin S
19. Fluorescence stopped flow analysis of the interaction of virginiamycin components and erythromycin with bacterial ribosomes
20. The lasting ribosome alteration produced by virginiamycin M disappears upon removal of certain ribosomal proteins
21. Competition between erythromycin and virginiamycin for in vitro binding to the large ribosomal subunit
22. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification
23. Intrinsic and unusual resistance to macrolide, lincosamide and streptogramin antibiotics in bacteria
24. Macrolide resistance
25. Erythromycin resistance by ribosome modification
26. Insights into erythromycin action from studies of its activity as inducer of resistance
27. The role of rRNA bases in the interaction of peptidyltransferase inhibitors with bacterial ribosomes
28. Identification of a single base change in ribosomal RNA leading to erythromycin resistance
29. Evidence for functional interaction between domain II and V of 23 S ribosomal RNA from an erythromycin resistant mutant
30. Functional interactions within 23S rRNA involving the peptidyltransferase center
31. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23 S ribosomal RNA
32. Identification of a site on 23 S ribosomal RNA located at the peptidyl transferase center
33. Altered methylation of ribosomal RNA in an erythromycin resistant strain of Staphylococcus aureus
34. Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics
35. Conformational alteration of mRNA structure and the posttrascriptional regulation of erythromycin-induced drug resistance
36. Post-transcriptional modification of mRNA conformation: Mechanism that regulates erythromycin induced resistance
37. Transcriptional attenuation control of ermK, a macrolide-lincosamide-streptogramin B resistance determinant from Bacillus licheniformis
38. Sequence of a staphylococcal gene vat, encoding an acetyltransferase inactivating the A-type compounds of virginiamycin-like antibiotics
39. B
40. Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics
41. Microbial transformation of peptide antibiotics. VI. Purification and properties of a peptide lactonase hydrolyzing dihydrostaphylomycin S
42. Studies on mikamycin B lactonase Degradation of mikamycin B by Streptomyces milakensis
43. Nucleotide sequence of a staphylococcal plasmid gene vgb, encoding a hydrolase inactivating the B components of virginiamycin-like antibiotic
44. Sequence of a staphylococcal plasmid gene vga, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics
45. Characterization of a new staphylococcal gene, vgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds
46. Characterization of a variant of vga(A) conferring resistance to streptogramin A and related compounds
47. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci and enterococci
48. Comparative in vitro activity of RP 59500
49. The in vitro activity of new streptogramins RP 59500, RP 57699 and RO 54476, alone and in combination
50. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates
51. Evaluation of in-vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
52. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
53. The life and times of the Enterococcus
54. Emergence of Enterococcus as a significant pathogen
55. Current perspectives on glycopeptide resistance
56. Resistance to glycopeptides in enterococci
57. The specter of glycopeptide resistance: Current trends and future considerations
58. Vancomycin-resistant enterococci
59. The efficacy and safety of quinupristin/dalfopristin from the treatment of infections caused by vancomycin-resistant Enterococcus faecium
60. Quinupristin/dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections
61. In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms
62. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR 106950): A novel orally administered streptogramin combination
63. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium
64. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium
65. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
66. Activity of the quinupristin/dalfopristin (RP 59500;Synercid) testing against vancomycin-resistant Enterococci species
67. In vitro activity of the RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci
68. In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species
69. Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals
70. In vitro activity of an orally administered streptogramin (RPR 106972) compared to quinupristin/dalfopristin and erythromycin
71. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin/dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin)
72. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sperfloxacin, temafloxacin, Win 57273, ofloxacin and ciprofloxacin
73. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology
74. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
75. In vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae
76. Distribution and antibiotic resistance of isolates from lower respiratory tract and blood culture from patients in three Italian intensive care units: A 2-year comparison
77. Methicillin-resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility
78. Emerging resistance to antimicrobial agents in Gram-positive bacteria
79. Current and future management of infections due to methicillin-resistant staphylococci: The role of quinupristin/dalfopristin
80. Comparative in vitro activities of quinupristin/dalfopristin RP 59500 against Gram-positive bloodstream isolates
81. In vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci
82. Comparative activity of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin and trovafloxacinand non-quinolones linezolid, quinupristin/dalfopristin, gentamicin and vancomycin against clinical isolates of cipr
83. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa
84. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro
85. Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP 59500, biapenem, trospectinomycin and piperacillin/tazobactam
86. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species
87. In vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp
88. In vitro activities for quinupristin/dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae
89. In vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies
90. In vitro bactericidal activity of RP 59500 (Synercid) against antibiotics resistant strains of Streptococcus pneumoniae and Enterococcus spp
91. Antipneumococcal activity of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin) and 8 oral β-lactams
92. Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics and initial clinical experience
93. A Phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500
94. Treatment of Gram-positive nosocomial pneumonia: Prospective randomised comparison of quinupristin/dalfopristin versus vancomycin
95. Treatment of hospitalised patients with complicated Gram-positive skin and skin structure infections: Two randomised multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin
96. Optimal treatment of complicated skin and skin structure infections